CN1246119A - 吡咯并[3,4－d]－嘧啶酮衍生物及其作为药物的用途 - Google Patents

吡咯并[3,4－d]－嘧啶酮衍生物及其作为药物的用途 Download PDF

Info

Publication number
CN1246119A
CN1246119A CN97181811A CN97181811A CN1246119A CN 1246119 A CN1246119 A CN 1246119A CN 97181811 A CN97181811 A CN 97181811A CN 97181811 A CN97181811 A CN 97181811A CN 1246119 A CN1246119 A CN 1246119A
Authority
CN
China
Prior art keywords
methyl
compound
pyrrolo
pyrimidine
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN97181811A
Other languages
English (en)
Chinese (zh)
Inventor
M·库珀
D·彻斯雷
D·多纳德
M·弗伯
M·佩尔里
R·哈里森
N·汤姆金森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRITISH ASTRA PHARMACEUTICALS Ltd
Original Assignee
BRITISH ASTRA PHARMACEUTICALS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BRITISH ASTRA PHARMACEUTICALS Ltd filed Critical BRITISH ASTRA PHARMACEUTICALS Ltd
Publication of CN1246119A publication Critical patent/CN1246119A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN97181811A 1996-12-21 1997-12-18 吡咯并[3,4－d]－嘧啶酮衍生物及其作为药物的用途 Pending CN1246119A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9626643.2 1996-12-21
GBGB9626643.2A GB9626643D0 (en) 1996-12-21 1996-12-21 Compounds

Publications (1)

Publication Number Publication Date
CN1246119A true CN1246119A (zh) 2000-03-01

Family

ID=10804862

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97181811A Pending CN1246119A (zh) 1996-12-21 1997-12-18 吡咯并[3,4－d]－嘧啶酮衍生物及其作为药物的用途

Country Status (23)

Country Link
US (8) US6046204A (https=)
EP (1) EP0946562B1 (https=)
JP (1) JP2001507687A (https=)
KR (1) KR20000069605A (https=)
CN (1) CN1246119A (https=)
AT (1) ATE215088T1 (https=)
AU (1) AU717429B2 (https=)
BR (1) BR9714063A (https=)
CA (1) CA2275312A1 (https=)
CZ (1) CZ289925B6 (https=)
DE (1) DE69711430T2 (https=)
EE (1) EE9900315A (https=)
GB (1) GB9626643D0 (https=)
HU (1) HUP0002839A3 (https=)
ID (1) ID21682A (https=)
IL (1) IL130538A0 (https=)
IS (1) IS5082A (https=)
NO (1) NO993027L (https=)
NZ (1) NZ336124A (https=)
PL (1) PL334228A1 (https=)
SK (1) SK76699A3 (https=)
TR (1) TR199901433T2 (https=)
WO (1) WO1998028301A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102238873A (zh) * 2008-12-06 2011-11-09 细胞内治疗公司 有机化合物
CN102695510A (zh) * 2009-08-10 2012-09-26 加利福尼亚大学董事会 囊性纤维化跨膜传导调节蛋白的嘧啶并-吡咯并-喹喔啉二酮抑制剂及其用途
CN108129486A (zh) * 2018-01-25 2018-06-08 华东理工大学 嘧啶酮衍生物及其用途

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
ATE294793T1 (de) 1999-01-15 2005-05-15 Altana Pharma Ag Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
CA2360386A1 (en) 1999-01-15 2000-07-20 Beate Gutterer Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
SI1147087T1 (en) 1999-01-15 2005-10-31 Altana Pharma Ag Phenanthridine-n-oxides with pde-iv inhibiting activity
US6361486B1 (en) * 2000-02-29 2002-03-26 Agilent Technologies, Inc. Coaxial-drive centrifuge providing tilt control relative to centrifugal force
HK1052509B (en) * 2000-08-14 2007-09-07 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazole
US20070105841A1 (en) * 2000-08-14 2007-05-10 Breitenbucher J G Method for treating allergies using substituted pyrazoles
TW200407315A (en) * 2002-04-23 2004-05-16 Sankyo Co Pyrimidine derivatives
CA2533534C (en) * 2003-07-24 2013-03-19 Tecomet, Inc. Assembled non-random foams
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
NZ572250A (en) 2006-05-04 2011-10-28 Pulmagen Therapeutics Inflammation Ltd Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
US8198288B2 (en) 2006-05-04 2012-06-12 Pulmagen Therapeutics (Inflammation) Limited Tetrahydropyrrolopyrimidinediones and their use in therapy
JP5453086B2 (ja) 2006-06-06 2014-03-26 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
ES2588238T3 (es) 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
WO2009100403A1 (en) * 2008-02-07 2009-08-13 Neurogen Corporation Substituted aryl pyrimidinones
KR20110098732A (ko) 2008-12-06 2011-09-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
AU2009322904A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
WO2012166658A1 (en) 2011-05-27 2012-12-06 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2436792A (en) * 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
GB9424842D0 (en) * 1994-12-09 1995-02-08 British Tech Group Pharmaceutical compositions

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102238873A (zh) * 2008-12-06 2011-11-09 细胞内治疗公司 有机化合物
CN102695510A (zh) * 2009-08-10 2012-09-26 加利福尼亚大学董事会 囊性纤维化跨膜传导调节蛋白的嘧啶并-吡咯并-喹喔啉二酮抑制剂及其用途
CN108129486A (zh) * 2018-01-25 2018-06-08 华东理工大学 嘧啶酮衍生物及其用途

Also Published As

Publication number Publication date
US6046204A (en) 2000-04-04
US6229013B1 (en) 2001-05-08
EP0946562B1 (en) 2002-03-27
IL130538A0 (en) 2000-06-01
DE69711430T2 (de) 2002-10-31
ID21682A (id) 1999-07-08
KR20000069605A (ko) 2000-11-25
ATE215088T1 (de) 2002-04-15
CZ220499A3 (cs) 2000-02-16
NO993027D0 (no) 1999-06-18
GB9626643D0 (en) 1997-02-12
EP0946562A1 (en) 1999-10-06
WO1998028301A1 (en) 1998-07-02
AU717429B2 (en) 2000-03-23
AU5580998A (en) 1998-07-17
TR199901433T2 (xx) 1999-09-21
SK76699A3 (en) 2000-05-16
BR9714063A (pt) 2002-01-02
US6136974A (en) 2000-10-24
PL334228A1 (en) 2000-02-14
EE9900315A (et) 2000-02-15
IS5082A (is) 1999-06-14
CZ289925B6 (cs) 2002-04-17
CA2275312A1 (en) 1998-07-02
US6211368B1 (en) 2001-04-03
JP2001507687A (ja) 2001-06-12
DE69711430D1 (de) 2002-05-02
NO993027L (no) 1999-08-20
US6306863B1 (en) 2001-10-23
HUP0002839A2 (hu) 2001-02-28
US20020025966A1 (en) 2002-02-28
US20030162798A1 (en) 2003-08-28
NZ336124A (en) 2001-03-30
US6166206A (en) 2000-12-26
HUP0002839A3 (en) 2001-04-28

Similar Documents

Publication Publication Date Title
CN1246119A (zh) 吡咯并[3,4－d]－嘧啶酮衍生物及其作为药物的用途
CN1259951A (zh) 新化合物
AU647859B2 (en) Anti-atherosclerotic aryl compounds
JP6916285B2 (ja) 嚢胞性線維症膜コンダクタンス制御因子の調節物質、医薬組成物、治療方法、及び調節物質の作製プロセス
JP5739446B2 (ja) ピロロ［２，３−ｄ］ピリミジン化合物
TWI294878B (en) Dioxan-2-ylalkylcarbamate derivatives, their preparation and their use in therapeutics
EP2518067B1 (fr) Dérives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide et leurs applications en thérapeutique comme antagonistes de p2y12.
KR20130143138A (ko) 관절염 치료에 유용한 신규 이미다졸 유도체
CN1483034A (zh) 吲哚衍生物及其作为5-ht2b和5-ht2c受体配体的应用
CN1382142A (zh) 作为p38蛋白激酶的抑制剂的烷基氨基－取代的双环氮杂环类化合物
CN1284079A (zh) 新化合物
JP2009543836A (ja) インドール化合物
CN87105516A (zh) 取代的苯基丁烯酰胺化合物及其制备方法
AU2023338957A1 (en) Modulators of alpha-1 antitrypsin
CN1048014C (zh) 取代的吡咯类化合物及其制法、药物组合物和用途
CN1301255C (zh) αLβ2整合素介导的细胞粘附抑制剂
CN1046517C (zh) 三唑并哒嗪,其制备和应用
CN1468233A (zh) 新颖的氨基三唑酮化合物、它们的制备方法和含有它们的药物组合物
EP1535920A1 (en) Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives
CN1054588A (zh) 侧链同系维生素d衍生物、其制备方法、含该类衍生物的医药制剂及其作医药的应用
CN1160075C (zh) 杂环酰胺化合物在制备IgE抗体产生抑制剂中的用途
AU2007212786B2 (en) Novel spiro[imidazolidine-4,3'-indole]-2,2',5(1'H)-triones for treatment of conditions associated with vanilloid receptor 1
CN1138852A (zh) 哒嗪酮衍生物
CN1798734A (zh) 作为蛋白激酶抑制剂的新化合物和组合物
CN1284878A (zh) 增强nkt细胞的药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Swedish Sodertalje

Applicant after: ASTRAZENECA AB

Address before: Hertfordshire

Applicant before: ASTRA PHARMACEUTICALS LTD.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: ASTRA PHARMACEUTICALS LTD. TO: ASTRAZENCA AB

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication